Purpose of the Immune Frame Test

• Provides a baseline immune status before starting RGCC cellular therapy.
• Screens for high-risk markers that may impact therapy effectiveness.
• It helps in monitoring immune response post-therapy every 6 months.

Pre-Therapy Testing Requirements

• Order within 3 months of planned cellular therapy.
• A CTC test is also required within the same timeframe.
• Identifies immune markers using ELISA and flow cytometry

Key Markers to Monitor

1. Markers to Lower (Negative Indicators):
   • TNF-a (Tumor Necrosis Factor-alpha): Should be as low as possible.
     • High TNF-a can be managed with:
       • Curcumin, EGCG (Green Tea), Resveratrol, Vitamin D3, Fish Oil, Magnesium, Ashwagandha, and Tart Cherry Juice.
     • Tregs (CD25, CTLA4): High levels indicate immune suppression.
       • Can be improved with:
         • Probiotics (e.g., Lactobacillus, Bifidobacterium), Fish Oil, Flavonoids, Vitamin D3, Ginger, and a Gluten-Free Diet.
2. Markers to Increase (Positive Indicators):
   • IL-2, IL-4, IL-6: Boost immune activation.
     • Supported by Melatonin, Mushroom Extracts, Vitamin C, Zinc, and Magnesium.
   • INF-γ (Interferon Gamma): Enhances immune response.
     • It can be improved using homeopathic Citomix (GUNA).
   • CD80/CD86/CD28: Key immune memory markers should gradually increase post-therapy.

Post-Therapy Monitoring

• Frequency: Every 6 months to track immune system improvement.
• Goal:
  • Decrease TNF-a and
  • Increase CD80/CD86 (>15% target), CD28 (>2.0 target).
• If CD80/86 levels reach >22, it indicates optimal immune response.

What is VAXO-Q-RE Therapy?

VAXO-Q-RE is an Autologous Adoptive Cellular Therapy designed to enhance the body's natural immune response to cancer. It uses a patient’s immune cells, including:

• Innate immunity: Macrophages and Natural Killer (NK) cells
• Adaptive immunity: Dendritic cells (DCs), Cytotoxic T-cells (CTLs), and plasma cells

How Does VAXO-Q-RE Work?

1. Blood is drawn from the patient.
2. Immune cells are isolated and expanded in the lab.
3. Adaptive immune cells are activated using personalized tumor antigens.
4. The prepared immune cells are infused back into the patient to fight cancer.

Who is Eligible for VAXO-Q-RE?

Suitable for:

• Solid tumors (all stages but primarily grade 2B or higher)
• Patients with stable disease who are not undergoing chemotherapy or radiation

Not suitable for:

• Central Nervous System cancers (due to the blood-brain barrier)
• Patients currently on chemotherapy, radiation, or immunosuppressants
• Individuals under 18 years old
• Pregnant or breastfeeding individuals
• Patients with active autoimmune diseases, infections, or cachexia

Pre-Therapy Requirements

• Mandatory Pre-tests:
  • Immune Frame (baseline immune status)
  • Oncotrace (circulating tumor cell count)
• Avoid the following prior to therapy:
  • Cytotoxic therapies (e.g., chemotherapy, radiation)
  • Immune-suppressing medications (at least 14 days)
  • Blood transfusions (at least 120 days)

Treatment Schedule

• Timeline: Three doses over 30 days
  • Day 0: 1st dose (Macrophages and NK cells)
  • Day 15: 2nd dose (APCs, CTLs, plasma cells)
  • Day 30: 3rd dose (based on patient needs)
• Follow-up tests:
  • Day 120: Immune Frame & Oncotrace
  • Day 210: Immune Frame & Oncotrace

Post-Therapy Recommendations

• Avoid cytotoxic and immune-suppressing treatments for 120 days after the final dose.
• Follow-up immune testing at 6-month intervals is recommended.
• If therapy response is insufficient, a booster dose may be recommended.

Expected Outcomes

• Increased immune response (CD80 >15%, CD86 >10%, CD28 >0)
• Long-term memory cell development for sustained immune protection

Possible Side Effects

• Flu-like symptoms
• Fatigue
• Fever
• Injection site reactions
• Tumor Lysis Syndrome (in cases with large tumor volume)